Intriguingly, a significant positive association was observed between hepatic transcript levels of CD36 and erythropoietin (EPO), a gene target dependent on HIF-2α, among NAFLD patients. The gene discussed is EPO; the disease is metabolic dysfunction-associated steatotic liver disease.